Given that high PDGFB expression is associated with poor survival outcomes in mIDH glioma, we sought to define how mutations to IDH alter PDGFB-chromatin interactions and to discern the effects of these alterations on gliomagenesis and progression. The gene discussed is IDH2; the disease is central nervous system cancer.